Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)
Public ClinicalTrials.gov record NCT03180684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva
Study identification
- NCT ID
- NCT03180684
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Enrollment
- 33 participants
Conditions and interventions
Conditions
Interventions
- CELLECTRA™ 2000 Device
- Imiquimod 5% Cream Drug
- VGX-3100 Biological
Device · Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 30, 2017
- Primary completion
- Jul 22, 2020
- Completion
- Dec 17, 2020
- Last update posted
- Aug 24, 2023
2017 – 2020
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Christiana Care Health Systems | Newark | Delaware | 19713 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| Rush University Medical Center | Chicago | Illinois | 60612 | — |
| Maine Medical Center | Scarborough | Maine | 04074 | — |
| University of Michigan | Ann Arbor | Michigan | 48109 | — |
| St. Dominic Hospital | Jackson | Mississippi | 39216 | — |
| Rutgers New Jersey | Newark | New Jersey | 07103 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Lyndhurst Clinical Research | Winston-Salem | North Carolina | 27103 | — |
| Complete HealthCare for Women, Inc. | Columbus | Ohio | 43231 | — |
| University of Pittsburgh Medical Center - Magee Womens Hospital | Pittsburgh | Pennsylvania | 15213 | — |
| Chattanooga's Program in Women's Oncology | Chattanooga | Tennessee | 37403 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37232-2519 | — |
| Froedtert and The Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03180684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 24, 2023 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03180684 live on ClinicalTrials.gov.